Can Tavalisse Drive Rigel's Growth Through the Rest of 2025?

Rigel Pharmaceuticals (RIGL) reported robust first-half 2025 sales, with its lead drug Tavalisse generating $68.5 million, a 44% year-over-year increase, complemented by rising sales from Rezlidhia and Gavreto. This strong performance led Rigel to significantly raise its 2025 total revenue guidance to $270-$280 million, up from $200-$210 million previously. However, the company faces increasing competitive pressure for Tavalisse following Sanofi's recent FDA approval of Wayrilz for ITP. Despite this emerging threat, RIGL shares have surged 116.9% year-to-date, outperforming industry benchmarks, and analyst EPS estimates for both 2025 and 2026 have seen substantial upgrades.

Analysis

Rigel Pharmaceuticals (RIGL) is demonstrating exceptional commercial momentum, driven by its lead product, Tavalisse. First-half 2025 sales for the drug reached $68.5 million, a 44% year-over-year increase fueled by strong new patient demand. This robust performance, complemented by sales growth from its other products Rezlidhia and Gavreto, prompted management to significantly raise its full-year 2025 total revenue guidance to $270-$280 million from a prior $200-$210 million. The market has responded favorably, with RIGL shares rallying 116.9% year-to-date, and analyst consensus EPS estimates for 2025 have more than doubled to $5.10. However, a significant forward-looking risk has emerged with the recent FDA approval of Sanofi's Wayrilz for the same ITP indication. While Tavalisse has a different mechanism of action, the commercial resources of a large pharmaceutical company like Sanofi pose a material competitive threat that could challenge Tavalisse's growth trajectory. Despite the stock's run-up, its price-to-sales ratio of 2.47 remains in line with the industry, though it is now above its five-year average, reflecting the market's pricing-in of recent operational success.

Key Decisions for Investors

• Investors should weigh the company's strong current sales momentum and significantly upgraded revenue guidance against the newly emerged competitive threat from Sanofi's Wayrilz.
• Monitor the initial sales data and market penetration of Wayrilz in the coming quarters, as this will be a primary determinant of Tavalisse's ability to sustain its growth rate.
• Given the stock's 116.9% year-to-date appreciation, much of the positive news may be priced in, so existing investors could consider taking some profits while new investors should be cautious about entry points until the competitive landscape becomes clearer.